Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. It is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.
52 Week high
52 Week low
Business Wire • 19 days ago • EXASAgilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
The Motley Fool • 22 days ago • EXASWhere Will Exact Sciences Be in 5 Years?
Zacks Investment Research • 24 days ago • EXASExact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
Zacks Investment Research • 24 days ago • EXASHere's Why You Should Retain Exact Sciences (EXAS) Stock Now
InvestorPlace • 25 days ago • EXASThe 3 Best Cathie Wood Stocks to Buy Now: September 2023
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.